Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Eagle Point Trinity Senior Secured Lending Capital Raise
Eagle Point Trinity Senior Secured Lending Company issued and sold 910.51 common shares for aggregate proceeds of $9,325. The private placement was conducted via subscription agreements and the share count was finalized on September 22, 2026.
Peoples Bancorp M&A Deal with Citizens National Corporation
Peoples Bancorp Inc. has received all necessary regulatory approvals for its pending acquisition of Citizens National Corporation and its subsidiary, Citizens Bank of Kentucky. The merger agreement, originally dated April 20, 2026, was previously approved by Citizens' shareholders in August 2026. This update confirms the removal of regulatory hurdles for the transaction, which will see Peoples as the surviving corporation.
Kimberly Clark Signs $7B M&A Deal with Kenvue Inc.
Kimberly-Clark announced a $7.0 billion exchange offer and consent solicitation for Kenvue Inc. notes as part of its pending acquisition of the company. The exchange offer allows holders of Kenvue notes to swap them for new Kimberly-Clark notes and cash, contingent on the merger closing which is expected in Q4 2026.
Tempest Therapeutics Research Collaboration with Factor Bioscience Inc. Worth $5M
Tempest Therapeutics entered into a Master Services Agreement and a specific work order with Factor Bioscience Inc. to develop in vivo CAR-T therapies. The agreement involves an estimated $5.0 million in annual fees and is considered a related-party transaction as Tempest's CEO, Dr. Matt Angel, is the majority owner and CEO of Factor Bioscience.
Beazer Homes USA Signs $350M M&A Deal with Dream Finders Homes, Inc.
Beazer Homes USA issued a conditional notice to redeem $350.0 million of its 7.250% Senior Notes due 2029. The redemption is contingent upon the closing of its previously announced merger with Dream Finders Homes, Inc., which is expected to occur on October 20, 2026. This filing provides a status and timeline update on the pending acquisition of Beazer Homes by Dream Finders Homes.
Grayscale Bittensor Trust (TAO) issued 151,900 shares in private placement transactions to accredited investors, raising approximately $0.89 million. The shares were issued at varying prices based on the Trust's Net Asset Value (NAV) per share in exchange for 2,869.42 TAO tokens. As of September 28, 2026, the Trust has a total of 2,994,200 shares issued and outstanding.
iQSTEL Inc. entered into an amendment to its acquisition agreement for GlobeTopper, LLC to settle a $500,000 purchase price obligation in cash rather than restricted common stock. The payment will be made in installments through early 2027 and is secured by the 51% membership interest in GlobeTopper originally acquired in 2025.
Scynexis Wins $214M Contract from Biomedical Advanced Research and Development Authority
SCYNEXIS was awarded a contract from BARDA providing up to $214 million in non-dilutive funding to support the development of SCY-247, a second-generation antifungal candidate. The agreement includes an initial $18.5 million base period to advance the candidate into Phase 2 studies for invasive candidiasis, with subsequent options that could fund the program through NDA submission.
Value
$214M
Counterparty
Biomedical Advanced Research and Development Authority (BARDA)
Term
up to 10 years
“We are proud to partner with BARDA to advance the development of SCY-247, our antifungal designed to address the growing threat of antimicrobial resistance.”
David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS
“While we remain focused on SCY-770, our new product candidate for ADPKD, this partnership enables the development of a novel therapy for the treatment and prevention of serious invasive fungal infections while leveraging our existing infrastructure and capabilities.”
David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS
Gossamer Bio has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, resolving a deficiency notice originally received on April 8, 2026. The company achieved compliance following a 1-for-80 reverse stock split that became effective on September 10, 2026, and the matter is now closed.
ADARx Pharmaceuticals closed its initial public offering (IPO) of 26,250,000 shares and a concurrent private placement of 5,255,542 shares to AbbVie Inc., both priced at $17.00 per share. The combined transactions generated approximately $535.6 million in gross proceeds, with AbbVie acquiring a 4.9% stake in the company.
Exascale Labs Holdings M&A Deal with Exascale Labs Inc.
Exascale Labs Holdings Inc. (formerly D. Boral ARC Merger Corporation) filed this amendment to provide required financial statements following the completion of its business combination with Exascale Labs Inc. The merger was consummated on August 27, 2026, resulting in Exascale Labs Inc. becoming a subsidiary of the public entity. This filing includes audited financial statements for Exascale Labs for the fiscal years ended June 30, 2026 and 2025.
Marygold Companies M&A Deal with Madison Dearborn Partners, LLC
The Marygold Companies (MGLD) entered into a definitive agreement to be acquired by funds managed by Madison Dearborn Partners (MDP) for $2.00 per share in cash. The transaction, which represents a 100% premium over the company's unaffected closing price, will result in Marygold becoming a privately held company. Following the merger, MDP plans to refocus the business on its USCF subsidiary, a commodity-focused ETF manager with approximately $6 billion in assets under management.
Coastal Financial Corporation's fintech partner, Bluevine, Inc., has entered into a definitive agreement to be acquired by Valley National Bancorp. Coastal Community Bank currently holds approximately $447 million in Bluevine-related deposits, but management does not expect the transaction to have a material adverse effect on the company's liquidity or funding profile due to its diversified partner platform.
CapsoVision received FDA clearance for AI Highlights, an AI-assisted reading tool for its CapsoCam Plus small bowel capsule endoscopy system. The tool is designed to reduce physician review time by automatically identifying and prioritizing images containing suspected abnormal lesions in patients with suspected small bowel bleeding.
Portland General Electric Signs $83M M&A Deal with Oregon Public Utility Commission
Portland General Electric (PGE) received a final order from the Oregon Public Utility Commission regarding its proposed reorganization into a holding company structure. While the order includes $83 million in customer benefits, it imposes restrictive conditions on dividends and credit ratings that PGE claims may prevent the reorganization from proceeding. The company is currently evaluating legal options, including judicial review, and does not expect to move forward with the deal unless the provisions are modified.
Proem Acquisition Corp. I Signs $50M M&A Deal with Astro Digital US, Inc.
Proem Acquisition Corp I (PAAC), a SPAC, has entered into a definitive merger agreement to acquire Astro Digital US, Inc., a satellite technology infrastructure company. The transaction includes a $50 million PIPE investment co-led by Proem Asset Management and Leon Capital Group, with the combined company expected to trade on Nasdaq under the name Astro Digital Holdings, Inc. in Q1 2027.
Columbus Acquisition M&A Deal with WISeSat.Space Corp
Columbus Acquisition Corp has adjourned its Extraordinary General Meeting of Shareholders to September 29, 2026, without conducting any business. The meeting is intended to vote on the proposed business combination with WISeSat.Space Corp. This represents a status update on a pending merger for the SPAC.
Greenpro Capital Corp. completed the sale of its F&A Entities, including Greenpro Resources (HK) Limited and several other subsidiaries, to Ms. Chen Yanhong for approximately $0.45 million in cash. The divested entities primarily provided corporate advisory and company-secretarial services in Hong Kong and China. The company plans to use the proceeds for general corporate purposes and will report these entities as discontinued operations starting in Q3 2026.
Getty Realty Corp. acquired a portfolio of 41 convenience store properties from Refuel Operating Company for $260.9 million in a sale-leaseback transaction. The properties, located across four states, were simultaneously leased back to Refuel under four unitary triple net leases with initial 20-year terms. The acquisition was funded through forward equity proceeds, unsecured debt, and property dispositions.
Kodiak Sciences announced that its Phase 3 DAYBREAK study in wet age-related macular degeneration (wAMD) met its primary endpoints for both Zenkuda and tabirafusp-ted. Both drugs demonstrated non-inferiority in vision gains compared to aflibercept, with Zenkuda showing 6-month durability in 54% of patients. The company plans to submit a multi-indication Biologics License Application (BLA) for Zenkuda in the fourth quarter of 2026.
Lifecore Biomedical, Inc. \De\ Signs $664M M&A Deal with Webster Equity Partners
Lifecore Biomedical has entered into a definitive agreement to be acquired by Webster Equity Partners for up to $663.7 million. Common stockholders will receive $6.28 per share in cash at closing plus contingent value rights (CVRs) worth up to an additional $160 million in aggregate based on performance milestones. The transaction represents a 49.5% premium to the company's last closing price and will result in Lifecore becoming a privately held company.
Silexion Therapeutics announced positive preclinical translational research findings for its lead RNAi candidate, SIL204, demonstrating a mechanism for systemic uptake in KRAS-driven cancers. The study showed that SIL204 utilizes native serum lipids and lipoprotein pathways for cellular entry and gene silencing without the need for artificial nanoparticles, supporting its upcoming Phase 2/3 clinical program.
Silicon Valley Acquisition M&A Deal with EigenQ, Inc.
Silicon Valley Acquisition Corp. (SVAQ) entered into a third amendment to its definitive business combination agreement with EigenQ, Inc. The amendment modifies the treatment of certain EigenQ warrants, clarifying they will be exchanged for PubCo warrants upon the closing of the merger. This filing provides a status update on the pending SPAC merger which will result in EigenQ becoming a wholly owned subsidiary of the domesticated Delaware corporation.
Bold Eagle Acquisition Signs $1.25B M&A Deal with REDLattice
Bold Eagle Acquisition Corp. (BEAG) has entered into a definitive business combination agreement to acquire REDLattice, a cyber intelligence platform for defense and national security, at a pre-money enterprise value of $1.25 billion. The transaction is supported by $335 million in committed capital, including a $60 million common stock investment, and will result in REDLattice becoming a publicly traded company on the Nasdaq under the ticker 'REDL'.
TransCode Therapeutics announced updated Phase 1a clinical trial data for TTX-MC138, showing a 71.4% stable disease rate in patients with advanced solid tumors. The study met its primary safety endpoint with no dose-limiting toxicities reported, and three patients remained progression-free at the one-year mark. The company believes the durability of disease control warrants continued clinical evaluation of the RNA-based therapeutic candidate.
Adicet Bio announced positive preliminary Phase 1 data for prula-cel in patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing a 50% complete renal response rate and 54% DORIS remission at 12 months. The therapy was generally well tolerated with no Grade 3 or higher CRS and no ICANS, supporting potential outpatient administration. Based on these results, the company plans to initiate pivotal trial start-up activities in the fourth quarter of 2026.
Volato Group Wins $1.17B Contract from a large AI customer
Volato Group's subsidiary, Alignment Engine, signed a Master Services Agreement and two initial orders with a large AI customer for dedicated AMD GPU infrastructure in Ohio. The aggregate contract value is approximately $1.17 billion over a four-year take-or-pay term, including $133 million in contractual prepayments. This represents a transformational milestone for the company's AI infrastructure platform.
4D Molecular Therapeutics announced the enrollment of the first patients in its 4SIGHT Phase 3 clinical trial evaluating 4D-150 for diabetic macular edema (DME). The company also released positive 2-year data from its SPECTRA clinical trial, showing 4D-150 was well tolerated with a 61% reduction in treatment burden compared to standard aflibercept injections.
The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older. The drug, licensed from Incyte, is a first-of-its-kind oral ALK2 inhibitor designed to reduce new heterotopic ossification (abnormal bone formation). Mirum expects the product to be commercially available in the U.S. in October 2026.
Ainos Licensing Deal with BioPhoenix Co., Ltd. Worth $10M
Ainos entered into a global exclusive license agreement with BioPhoenix for its VELDONA low-dose oral interferon alpha technology platform for Sjögren’s Disease and Thrombocytopenia. Ainos will receive an upfront fee of $600,000 and is eligible for up to $10.0 million in total fees if additional indications are licensed, plus 25% of net sublicensing revenue. BioPhoenix will assume all clinical and regulatory funding and execution for the licensed indications.